Wall Street brokerages expect that TESARO Inc (NASDAQ:TSRO) will report $51.73 million in sales for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for TESARO’s earnings, with estimates ranging from $46.07 million to $59.17 million. TESARO reported sales of $4.23 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 1,122.9%. The firm is expected to announce its next quarterly earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that TESARO will report full year sales of $51.73 million for the current fiscal year, with estimates ranging from $221.37 million to $299.10 million. For the next fiscal year, analysts expect that the business will post sales of $414.58 million per share, with estimates ranging from $288.90 million to $529.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover TESARO.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.16) by $0.69. The firm had revenue of $142.77 million during the quarter, compared to analysts’ expectations of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The business’s quarterly revenue was up 740.3% on a year-over-year basis. During the same quarter last year, the firm earned ($1.72) EPS.

A number of equities analysts recently issued reports on the company. Robert W. Baird restated a “neutral” rating and issued a $125.00 target price on shares of TESARO in a research note on Monday, October 2nd. Citigroup restated a “buy” rating and issued a $135.00 target price (down previously from $216.00) on shares of TESARO in a research note on Wednesday, December 20th. Piper Jaffray Companies restated a “hold” rating and issued a $80.00 target price on shares of TESARO in a research note on Tuesday. Jefferies Group restated a “hold” rating and issued a $124.00 target price on shares of TESARO in a research note on Friday, November 3rd. Finally, Oppenheimer restated a “buy” rating and issued a $199.00 target price on shares of TESARO in a research note on Sunday, September 10th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. TESARO presently has a consensus rating of “Buy” and a consensus price target of $152.64.

TESARO (TSRO) opened at $75.62 on Wednesday. The stock has a market capitalization of $4,110.00, a price-to-earnings ratio of -8.97 and a beta of 1.52. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35. TESARO has a 52 week low of $74.57 and a 52 week high of $192.94.

In related news, SVP Martin H. Jr. Huber sold 829 shares of TESARO stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the sale, the senior vice president now directly owns 8,101 shares in the company, valued at approximately $690,529.24. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 34.60% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in TESARO by 5.7% in the 2nd quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock worth $504,230,000 after buying an additional 195,590 shares during the last quarter. Vanguard Group Inc. boosted its holdings in TESARO by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock worth $416,537,000 after buying an additional 62,104 shares during the last quarter. State Street Corp boosted its holdings in TESARO by 17.9% in the 2nd quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock worth $163,496,000 after buying an additional 177,057 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in TESARO by 24.9% in the 3rd quarter. Janus Henderson Group PLC now owns 895,556 shares of the biopharmaceutical company’s stock worth $115,616,000 after buying an additional 178,406 shares during the last quarter. Finally, BB Biotech AG boosted its holdings in shares of TESARO by 6.5% during the 2nd quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock worth $122,796,000 after purchasing an additional 53,408 shares during the last quarter.

TRADEMARK VIOLATION WARNING: “Analysts Expect TESARO Inc (TSRO) Will Announce Quarterly Sales of $51.73 Million” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/03/analysts-expect-tesaro-inc-tsro-will-announce-quarterly-sales-of-51-73-million.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Get a free copy of the Zacks research report on TESARO (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.